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Abstract
The asymmetric total synthesis of pyranicin (1) is reported. The butenolide ring was constructed via
an asymmetric alkylation/ring-closing metathesis strategy. The three stereocenters in the left-hand
tetrahydropyran ring were installed by sequential chiral auxiliary-mediated aldol reactions. Closure
of the tetrahydropyran and fusion of the alkyl backbone were affected via a sequential ring-closing
metathesis cross-metathesis strategy.
Pyranicin (1), a novel member of the annonaceous acetogenin family of natural products, was
isolated in 1997 by McLaughlin and coworkers from the stem bark of the Goniothalamus
giganteus tree native to Thailand.1 Since 1982, over 400 molecules in the annonaceous
acetogenin family have been identified, but pyranicin is one of only two known acetogenins
to bear a tetrahydropyran (THP) ring.2 These 35- or 37-carbon polyether natural products
typically possess a terminal γ-methylbutenolide, and are capped with a long hydrophobic alkyl
chain. Annonaceous acetogenins are the most powerful inhibitors of mitochondrial Complex
I (NADH-ubiquinone oxidoreductase) in both mammalian and insect electron transport
systems. It is believed that their ability to interrupt the final electron transfer from NADH to
ubiquinone decreases cellular ATP production, leading to cell death by apoptosis. This unique
mode of biological activity has characterized the acetogenins as promising anti-feedant and
pesticide treatments, as well as anti-malarial, anti-parasitic, and anti-tumor drugs, and they
have recently exhibited promising results against Parkinsonism.3 Pyranicin, in particular,
demonstrates selective in vitro cytotoxicity (ED50 10−2 μg/mL) against human pancreatic
adenocarcinomal cell lines (PACA-2).1 Recent studies have further revealed in vivo
cytotoxicity (ID50 9.4 μM) of pyrancin against the growth of promyelocytic leukemia cells
(HL-60), alternatively attributed to its ability to inhibit DNA polymerase in the cancerous cells.
4 The interesting structures and and potent bilogical activity have made the annonaceous
acetogenins the subject of a significant amount of synthetic work.5 The first total synthesis of
pyranicin was accomplished by Nakata and Takahashi6 with subsequent reports by Rein,7
Makabe8 and Phillips.9
Herein we describe an enantioselective total synthesis of pyranicin, taking advantage of
chlorotitanium enolates of N-glycolyloxazolidinones to establish the syn 1,2-oxygen
relationship at C15–C16 and C19–C20.10 The pyranicin carbon backbone was envisioned to
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arise from a tandem ring-closing metathesis (RCM) - cross metathesis (CM) reaction that would
close the tetrahydropyran ring from triene 2 while concurrently joining the tetrahydropyran
unit and butenolide fragment 3 (Figure 1). Dihydropyran precursor 2 would be accessed via
an asymmetric glycolate aldol addition of glycolyloxazolidinone 4 and aldehyde 5. The
butenolide ring would be constructed via esterification of acrylic acid 7 with (S)-3-buten-2-ol
(6), followed by RCM.
Aldehyde 5 was prepared from (S)-benzylglycidyl ether as illustrated in Scheme 1. Lewis acid
promoted addition11 of lithiated homopropargyl alcohol 8 to (S)-benzyl glycidyl ether provided
alkyne 9. The alkyne was reduced and removal of the benzyl group was accomplished
employing Raney nickel to deliver diol 10. Selective sulfonylation of the primary alcohol was
best affected employing 2,4,6-triisopropylsulfonylchloride (TrisCl) under standard conditions
whereupon treatment with base afforded epoxide 11. Subsequently, the (S)-epoxide underwent
copper (I) promoted reaction with butenylmagnesium bromide to provide alcohol 12. Ensuing
alcohol protection, selective removal of the PMB ether,12 and Swern oxidation13 of the primary
alcohol provided the target aldehyde 5 in good yield over three steps.
Preparation of triene 2 began with a glycolate aldol reaction between
benzylglycolyloxazolidinone 13 and tridecanal, providing aldol adduct 14 in good yield and
excellent diastereoselectivity (Scheme 1).10 This reaction established the stereocenters at C19
and C20 at an early stage. The secondary alcohol was then protected as its triethylsilyl (TES)
ether, and the chiral auxiliary was reductively removed with lithium borohydride.
Oxidation13 of primary alcohol 15 followed by Wittig methylenation provided the protected
diol, which was selectively deprotected under fluoride conditions to give secondary alcohol
16. Subsequent alkylation of the free alcohol with bromoacetic acid gave the glycolic acid, and
further transformation into glycolylimide 4 was accomplished via nucleophilic addition of
lithiated oxazolidinone 17 to the intermediate mixed pivaloyl anhydride.14
A second titanium-mediated glycolate aldol reaction10 with aldehyde 5 established the
stereocenters at C15 and C16 providing the aldol adduct 18 in 74% yield (>95:5 dr). The RCM
precursor 2 was prepared from aldol adduct 18 by a four step sequence. Protection of the C15
hydroxyl as its TES ether followed by reductive removal of the auxiliary gave the primary
alcohol 19. Dess-Martin oxidation15 of the alcohol to the aldehyde and final methylenation
completed the synthesis of triene 2.
Our efforts were directed next towards the preparation of γ-methylbutenolide 3. The C34
stereocenter was to be installed via esterifcation using (S)-3-buten-2-ol (6). Although the
enantiomer of the alcohol had previously been prepared in our total synthesis of giganticin,
16 the volatility of the alcohol (bp = 92 °C) created difficulty with its successful isolation. In
an attempt to ease the problems with isolation of alcohol 6, while still maintaining the necessary
terminal olefin functionality for the ensuing RCM reaction, we investigated the use of alcohol
22 in an alternative relay ring-closing metathesis (RRCM) strategy, recently demonstrated by
Hoye17 (Scheme 2). We anticipated that while the increased molecular weight of the ether
fragment of alcohol 22 would effectively improve the isolation of the chiral alcohol, the
additional atoms would be removed as dihydrofuran during the ensuing relay metathesis,
providing butenolide 3. The synthesis of bis-allylic ether 22 was thus pursued. L-Ethyl lactate
was protected as its t-butyldiphenylsilyl (TBDPS) ether 20, which was subsequently reduced
to the corresponding aldehyde (Scheme 2). Olefination of the intermediate aldehyde employing
carboethoxymethylene triphenylphsophorane yielded α,β-unsaturated ester 21, which was then
reduced to the allylic alcohol. Alkylation of the alcohol with allyl bromide gave the allyl ether,
which was exposed to n-Bu4NF to provide the desired alcohol 22 in 80% over two steps.
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The synthesis of acrylate 7 began with installation of the C4 stereocenter via asymmetric
alkylation18 of p-methoxybenzylglycolyloxazolidinone 23 with allylic iodide 24,19 giving
protected allyl alcohol 25 with high (>95:5) diastereoselectivity (Scheme 2). Reductive
removal of the chiral auxiliary unmasked a primary alcohol 26, which allowed for conversion
to the terminal alkene via Swern13 oxidation and subsequent olefination with
methylenetriphenylphsophorane. Removal of the primary TBS ether followed by a two-stage
oxidation yielded the corresponding acrylic acid 7. Esterification of acid 7 with alcohol 22 was
best affected via the intermediate mixed pivaloyl anhydride. Initial attempts at closure of the
butenolide under standard RRCM conditions only gave the corresponding ring-opened diene
29, presumably formed after the initial expulsion of dihydrofuran, followed by intermolecular
carbene transfer. However, by sparging the reaction with argon, we were able to increase the
yield of butenolide 3 from 23% to 70%, without any trace of straight-chain byproduct 29.20
The completion of the synthesis required the closure of the tetrahydropyran ring via a ring-
closing metathesis and assembly of the THP and butenolide fragments through a cross-
metathesis reaction (Scheme 3). Given the expected rapid closure of the tetrahydropyran and
the difference in reactivity between the C5 alkene of the butenolide and the C6 alkene of the
tetrahydropyran unit, it was hoped that the two processes could be accomplished concurrently
in a single exposure to a ruthenium carbene.21
Despite the differences in the reactivities of the two coupling fragments, however, the ensuing
tandem RCM/CM reaction proved to be quite difficult to control and suitable conditions for
the tandem sequence could not be identified. The best results were found when the cross
metathesis was performed between the ring-closed monomer 30 and butenolide 3. Therefore,
it was necessary to isolate the ring-closed monomer before subjecting to cross metathesis with
butenolide 3. In the event, triene 2 was exposed to the Grubbs second generation catalyst22 to
close the tetrahydropyran ring. After the ring-closing metathesis product 30 was isolated in
quantitative yield, the cross metathesis between alkene 30 and butenolide 3 was achieved with
the Hoveyda-Grubbs catalyst23 in 58% yield based on recovered starting material.
Finally, exposure of triene 31 to excess tosylhydrazine and sodium acetate in aqueous
dimethoxyethane at reflux,24 resulted in selective hydrogenation of the C17–C18 and C5–C6
alkenes and removal of the triethylsilyl protecting group, while leaving the butenolide olefin
in tact. Subjection of the resultant butenolide to BF3-OEt2 - in dimethyl sulfide provided
pyranicin (1) in 68% yield. The synthetic sample was identical in all aspects (1H, 13C, [a]D) to
the natural product.1
In summary, a highly convergent total synthesis of pyranicin (1) has been completed. The key
fragments were constructed employing asymmetric glycolate aldol and alkylation reactions
followed by ring-closing metatheses; a cross metathesis was utilized to convergently construct
the backbone of the natural product.
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Original retrosynthesis of pyranicin
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Preparation of triene 2
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Preparation of butenolide 3
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Completion of the synthesis
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